UroGen Pharma Ltd.

Healthcare

NASDAQ:URGN · NASDAQ Global Market

Market Cap $1.38B Beta 1.62 P/E (TTM) -11.2

$29.72 +0.75%

+$0.22 today

52W Low $11.51High $32.37

Vol 0.58M · Avg 0.80M

EPS (TTM)-$2.65

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+147.05%

Period High

$31.33

Period Low

$12.03

Latest

$29.72

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Tango Therapeutics, Inc.

NASDAQ:TNGX

$3.59B

AnaptysBio, Inc.

NASDAQ:ANAB

$2.42B

Kodiak Sciences Inc.

NASDAQ:KOD

$1.80B

Mind Medicine (MindMed) Inc.

MNMD

$1.56B

Nurix Therapeutics, Inc.

NASDAQ:NRIX

$1.47B

Xencor, Inc.

NASDAQ:XNCR

$914.17M

Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

$827.07M

Oculis Holding AG

NASDAQ:OCS

$634.01M

BridgeBio Oncology Therapeutics Inc.

NASDAQ:BBOT

$620.83M

ProKidney Corp.

NASDAQ:PROK

$242.99M

What is the latest URGN filing?

The latest filing shown is 4 dated Jun 9, 2026.

How many recent filings does URGN have?

Intrinsic Alpha currently shows 20 recent filings for URGN.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.